$92.78
-0.47 (-0.50%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
-14.01%
1Y
+102.22%
YTD
-7.73%
Open$94.99
Previous Close$93.25
Day High$95.16
Day Low$90.39
52W High$151.02
52W Low$42.38
Volume—
Avg Volume1.10M
Market Cap4.44B
P/E Ratio—
EPS$-3.90
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$105.59
Below
SMA 200
$59.11
Above
RSI (14)
39.6
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
18 analysts
Price Target
-72.5% upside
Current
$92.78
$92.78
Target
$25.56
$25.56
$16.07
$25.56 avg
$38.64
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 856.50M | 842.65M | 828.36M |
| Net Income | -244,490,059 | -213,463,076 | -182,555,570 |
| Profit Margin | -28.6% | -25.3% | -22.0% |
| EBITDA | -292,781,484 | -259,398,727 | -297,826,578 |
| Free Cash Flow | -124,649,561 | -156,876,378 | -179,431,543 |
| Rev Growth | +6.2% | -3.6% | +12.6% |
| Debt/Equity | 1.11 | 1.11 | 1.34 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |